In non-small cell lung cancer (NSCLC), the cancer stem cell population showed less apoptotic response after cisplatin treatment, as demonstrated by diminished cleavage of PARP from full-length fragment and caspase 3 activation [41]. This evidence concerns the gene CASP3 and non-small cell lung carcinoma.